Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Status:
Recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and
preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations,
including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other
advanced solid tumors.